B
BridgeBio
Biotech & Life Sciences · Palo Alto, United States · Founded 2014 · IPO 2019 Decacorn
Focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform
Global footprint
Where BridgeBio has talent and traffic
(2 of 916 staff)
team presence
across markets
Capital deployed
BridgeBio's 7 investments and acquisitions.
Every disclosed deal where BridgeBio appeared as a backer or acquirer, 2014–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
7 deals across BridgeBio's capital deployment.
Where the deals concentrate by sector, stage, and decade.
02 · Portfolio market map
BridgeBio's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Sentiment on X
What X is saying about BridgeBio
An AI-synthesized read of the highest-engagement posts about BridgeBio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BridgeBio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.